We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
While secondary T-cell cancers following CAR-T cell therapy are relatively rare adverse events, the FDA wants its new boxed warning labeling changes for the drugs to encourage more data on outcomes, agency officials said in an editorial. Read More
The Department of Justice (DOJ) and HHS issued a joint letter to state Medicaid administrators urging them to act in accordance with the Americans with Disabilities Act (ADA) and allow access to life-saving hepatitis C medications to people who have both hepatitis C and substance use disorder. Read More
The Biden administration and Danco Laboratories, manufacturer of the abortion pill mifepristone, have filed briefs petitioning the Supreme Court to keep wider patient access because restricting the drug would have damaging health repercussions for women. Read More
An Illinois law that targets “price gouging” for generic drugs is the target of a lawsuit filed by the trade group representing America’s generics and biosimilar manufacturers who claim the law is a constitutional overreach that would have Illinois regulating transactions outside that state. Read More
The Canadian government is not happy with the FDA’s decision to allow the state of Florida to import certain Canadian prescription drugs in bulk, and neither is the powerful U.S. pharmaceutical industry trade group PhRMA. Read More
Two significant changes in the FDA’s final guidance on updating ANDA labeling are details on how to obtain information on changes to reference listed drug (RLD) labeling and how to submit revised ANDA labeling. Read More
Less than two months after its announced investigation of secondary T-cell cancers in patients who received chimeric antigen receptor (CAR)-T cell immunotherapy cancer treatments, the FDA is mandating label updates to include a boxed warning, the agency’s most serious drug safety alert. Read More
The European Medicines Agency (EMA) has released a major revision of its user guide for micro, small, and medium-sized enterprises (SME) in the pharmaceutical sector, including updates to reflect new EU regulations, guidance for working with technology and data and collaborating outside the EU. Read More